1. Furst, DE, Amato, AA, Iorga, S¸R, et al. Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan. Muscle Nerve 2012; 45: 676–683.
Google Scholar | Crossref | Medline2. Svensson, J, Arkema, EV, Lundberg, IE, et al. Incidence and prevalence of idiopathic inflammatory myopathies in Sweden: a nationwide population-based study. Rheumatology 2017; 56: 802–810.
Google Scholar | Crossref | Medline3. Cho, S-K, Kim, H, Myung, J, et al. Incidence and prevalence of idiopathic inflammatory myopathies in Korea: a nationwide population-based study. J Korean Med Sci 2019; 34: e55.
Google Scholar | Crossref | Medline4. Betteridge, Z, Tansley, S, Shaddick, G, et al. Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. J Autoimmun 2019; 101: 48–55.
Google Scholar | Crossref | Medline5. Lega, JC, Fabien, N, Reynaud, Q, et al. The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome. Autoimmun Rev 2014; 13: 883–891.
Google Scholar | Crossref | Medline | ISI6. Marie, I, Hachulla, E, Cherin, P, et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 2002; 47: 614–622.
Google Scholar | Crossref | Medline7. Johnson, C, Pinal-Fernandez, I, Parikh, R, et al. Assessment of mortality in autoimmune myositis with and without associated interstitial lung disease. Lung 2016; 194: 733–737.
Google Scholar | Crossref | Medline8. Marie, I, Hatron, PY, Dominique, S, et al. Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Arthritis Rheum 2011; 63: 3439–3447.
Google Scholar | Crossref | Medline9. Nuno-Nuno, L, Joven, BE, Carreira, PE, et al. Mortality and prognostic factors in idiopathic inflammatory myositis: a retrospective analysis of a large multicenter cohort of Spain. Rheumatol Int 2017; 37: 1853–1861.
Google Scholar | Crossref | Medline10. Yamasaki, Y, Yamada, H, Ohkubo, M, et al. Long term survival and associated risk factors in patients with adult-onset idiopathic inflammatory myopathies and amyopathic dermatomyositis: experience in a single institute in Japan. J Rheumatol 2011; 38: 1636–1643.
Google Scholar | Crossref | Medline | ISI11. Marie, I, Josse, S, Decaux, O, et al. Clinical manifestations and outcome of anti-PL7 positive patients with antisynthetase syndrome. Eur J Intern Med 2013; 24: 474–479.
Google Scholar | Crossref | Medline12. Moghadam-Kia, S, Oddis, CV, Sato, S, et al. Antimelanoma differentiation-associated gene 5 antibody: expanding the clinical spectrum in North American patients with dermatomyositis. J Rheumatol 2017; 44: 319–325.
Google Scholar | Crossref | Medline13. Hoa, S, Troyanov, Y, Fritzler, MJ, et al. Describing and expanding the clinical phenotype of anti-MDA5-associated rapidly progressive interstitial lung disease: case series of nine Canadian patients and literature review. Scand J Rheumatol 2018; 47: 210–224.
Google Scholar | Crossref | Medline14. Tsuji, H, Nakashima, R, Imura, Y, et al. Efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung disease accompanied by anti-MDA5-positive-dermatomyositis – a multicenter prospective study. Chicago, IL: American College of Rheumatology, 2018.
Google Scholar15. Huapaya, JA, Silhan, L, Pinal-Fernandez, I, et al. Long-term treatment with azathioprine and mycophenolate mofetil for myositis-related interstitial lung disease. Chest 2019; 156: 896–906.
Google Scholar | Crossref | Medline16. Ji, S-y, Zeng, F-q, Guo, Q, et al. Predictive factors and unfavourable prognostic factors of interstitial lung disease in patients with polymyositis or dermatomyositis: a retrospective study. Chin Med J 2010; 123: 517–522.
Google Scholar | Medline | ISI17. Suzuki, Y, Hayakawa, H, Miwa, S, et al. Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis. Lung 2009; 187: 201–206.
Google Scholar | Crossref | Medline | ISI18. Doyle, TJ, Dhillon, N, Madan, R, et al. Rituximab in the treatment of interstitial lung disease associated with antisynthetase syndrome: a multicenter retrospective case review. J Rheumatol 2018; 45: 841–850.
Google Scholar | Crossref | Medline19. Andersson, H, Sem, M, Lund, MB, et al. Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease. Rheumatology 2015; 54: 1420–1428.
Google Scholar | Crossref | Medline20. Kurita, T, Yasuda, S, Oba, K, et al. The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis. Rheumatology 2015; 54: 39–44.
Google Scholar | Crossref | Medline | ISI21. Suzuka, T, Kotani, T, Takeuchi, T, et al. Efficacy and safety of oral high-trough level tacrolimus in acute/subacute interstitial pneumonia with dermatomyositis. Int J Rheum Dis 2019; 22: 303–313.
Google Scholar | Crossref | Medline22. Sharma, N, Putman, MS, Vij, R, et al. Myositis-associated interstitial lung disease: predictors of failure of conventional treatment and response to tacrolimus in a US cohort. J Rheumatol 2017; 44: 1612–1618.
Google Scholar | Crossref | Medline23. Allenbach, Y, Uzunhan, Y, Toquet, S, et al. Different phenotypes in dermatomyositis associated with anti-MDA5 antibody. Neurology 2020; 95: e70.
Google Scholar | Crossref | Medline24. Chen, Z, Wang, X, Ye, S. Tofacitinib in amyopathic dermatomyositis–associated interstitial lung disease. N Engl J Med 2019; 381: 291–293.
Google Scholar | Crossref | Medline25. Abe, Y, Matsushita, M, Tada, K, et al. Clinical characteristics and change in the antibody titres of patients with anti-MDA5 antibody-positive inflammatory myositis. Rheumatology 2017; 56: 1492–1497.
Google Scholar | Crossref | Medline26. Romero-Bueno, F, Diaz Del Campo, P, Trallero-Araguás, E, et al. Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease. Semin Arthritis Rheum 2020; 50: 776–790.
Google Scholar | Crossref | Medline27. Lancaster, L, Crestani, B, Hernandez, P, et al. Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials. BMJ Open Respir Res 2019; 6: e000397.
Google Scholar | Crossref | Medline28. Vasakova, M, Sterclova, M, Mogulkoc, N, et al. Long-term overall survival and progression-free survival in idiopathic pulmonary fibrosis treated by pirfenidone or nintedanib or their switch. Real world data from the EMPIRE registry. Eur Respir J 2019; 54: PA4720.
Google Scholar29. Flaherty, KR, Wells, AU, Cottin, V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med 2019; 381: 1718–1727.
Google Scholar | Crossref | Medline30. Tashkin, DP, Elashoff, R, Clements, PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655–2666.
Google Scholar | Crossref | Medline | ISI31. Tashkin, DP, Roth, MD, Clements, PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med 2016; 4: 708–719.
Google Scholar | Crossref | Medline32. Md Yusof, MY, Kabia, A, Darby, M, et al. Effect of rituximab on the progression of rheumatoid arthritis–related interstitial lung disease: 10 years’ experience at a single centre. Rheumatology 2017; 56: 1348–1357.
Google Scholar | Crossref | Medline33. Vadillo, C, Nieto, MA, Romero-Bueno, F, et al. Efficacy of rituximab in slowing down progression of rheumatoid arthritis–related interstitial lung disease: data from the NEREA Registry. Rheumatology 2020; 59: 2099–2108.
Google Scholar | Crossref | Medline34. Oddis, CV, Reed, AM, Aggarwal, R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 2013; 65: 314–324.
Google Scholar | Crossref | Medline35. Fernández-Díaz, C, Castañeda, S, Melero-González, RB, et al. Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients. Rheumatology 2020; 59: 3906–3916.
Google Scholar | Crossref | Medline36. Chung, L, Spino, C, McLain, R, et al. Safety and efficacy of abatacept in early diffuse cutaneous systemic sclerosis (ASSET): open-label extension of a phase 2, double-blind randomised trial. Lancet Rheumatol 2020; 2: e743–e753.
Google Scholar | Crossref37. King, TE, Bradford, WZ, Castro-Bernardini, S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083–2092.
Google Scholar | Crossref | Medline | ISI38. Richeldi, L, du Bois, RM, Raghu, G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071–2082.
Google Scholar | Crossref | Medline | ISI39. Distler, O, Highland, KB, Gahlemann, M, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med 2019; 380: 2518–2528.
Google Scholar | Crossref | Medline40. Highland, KB, Distler, O, Kuwana, M, et al. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial. Lancet Respir Med 2021; 9: 96–106.
Google Scholar | Crossref | Medline41. Bizargity, P, Liu, K, Wang, L, et al. Inhibitory effects of pirfenidone on dendritic cells and lung allograft rejection. Transplantation 2012; 94: 114–122.
Google Scholar | Crossref | Medline42. Toda, M, Mizuguchi, S, Minamiyama, Y, et al. Pirfenidone suppresses polarization to M2 phenotype macrophages and the fibrogenic activity of rat lung fibroblasts. J Clin Biochem Nutr 2018; 63: 58–65.
Google Scholar | Crossref | Medline43. Iyer, SN, Hyde, DM, Giri, SN. Anti-inflammatory effect of pirfenidone in the bleomycin-hamster model of lung inflammation. Inflammation 2000; 24: 477–491.
Google Scholar | Crossref | Medline44. Trivedi, R, Redente, EF, Thakur, A, et al. Local delivery of biodegradable pirfenidone nanoparticles ameliorates bleomycin-induced pulmonary fibrosis in mice. Nanotechnology 2012; 23: 505101.
Google Scholar | Crossref | Medline45. Visner, GA, Liu, F, Bizargity, P, et al. Pirfenidone inhibits T-cell activation, proliferation, cytokine and chemokine production, and host alloresponses. Transplantation 2009; 88: 330–338.
Google Scholar | Crossref | Medline46. Kahn, JS, Deverapalli, SC, Rosmarin, DM. JAK-STAT signaling pathway inhibition: a role for treatment of discoid lupus erythematosus and dermatomyositis. Int J Dermatol 2018; 57: 1007–1014.
Google Scholar | Crossref | Medline47. Yan, W, Fan, W, Chen, C, et al. IL-15 up-regulates the MMP-9 expression levels and induces inflammatory infiltration of macrophages in polymyositis through regulating the NF-kB pathway. Gene 2016; 591: 137–147.
Google Scholar | Crossref |